Suppression of amiodarone-induced torsade de pointes by landiolol in a patient with atrial fibrillation-mediated cardiomyopathy.

Abstract

An elderly Japanese woman developed acute decompensated heart failure caused by persistent atrial fibrillation (AF) and left ventricular systolic dysfunction. Approximately 6 days after starting intravenous administration of amiodarone (600 mg/day) for maintaining sinus rhythm after cardioversion of AF, electrocardiograms revealed a prolonged QT interval associated with torsade de pointes (TdP). The amiodarone-induced TdP disappeared after intravenous administration of landiolol plus magnesium and potassium, without discontinuation of amiodarone or overdrive cardiac pacing, although the prolonged QT interval persisted. To the best of our knowledge, this is the first report that landiolol could be effective for amiodarone-induced TdP.

• Authors: Koji Takahashi, Mina Yamashita, Tomoki Sakaue, Daijiro Enomoto, Shigeki Uemura, Takafumi Okura, Shuntaro Ikeda, Masafumi Takemoto, Yutaka Utsunomiya, Takashi Hyodo
• Journal: Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc (Ann Noninvasive Electrocardiol) Vol. 26 Issue 6 Pg. e12842 (11 2021) ISSN: 1542-474X [Electronic] United States
• PMID: 33755267 (Publication Type: Case Reports)
• Copyright: © 2021 The Authors. Annals of Noninvasive Electrocardiology published by Wiley Periodicals LLC.

Chemical References

• Anti-Arrhythmia Agents
• Morpholines
• landiolol
• Urea
• Amiodarone

Topics

• Aged
• Amiodarone (adverse effects)
• Anti-Arrhythmia Agents (adverse effects)
• Atrial Fibrillation (drug therapy)
• Cardiomyopathies
• Electrocardiography
• Female
• Humans
• Morpholines
• Torsades de Pointes (chemically induced, drug therapy)
• Urea (analogs & derivatives)